Navigation Links
VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors
Date:5/22/2008

Rigel Pharmaceuticals CMO to Add Valuable Clinical Development Expertise

SAN DIEGO, May 22 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and autoimmune diseases, announced today the appointment of Dr. Elliott Grossbard to its Board of Directors.

"We are pleased to have Elliott join our Board of Directors," said Michael Kamdar, Executive Vice President and Chief Business Officer at VentiRx. "We look forward to working closely with Elliott as we advance the first selective TLR8 agonists into the clinic this fall. His insights and experience will be invaluable as we embark into clinical development in 2008."

"I am pleased to be joining the Board of VentiRx," said Dr. Grossbard. "VentiRx is a rapidly emerging company equipped with a talented management team and very interesting clinical development candidates in oncology and allergy. I look forward to working with management and the other members of the Board to advance these novel molecules and build a successful company."

"We welcome Elliott to the Board," said Dr. Robert Hershberg, Executive Vice President and Chief Medical Officer at VentiRx. "Elliott brings to VentiRx a long history of clinical development expertise in therapeutic areas that are vital for us."

Dr. Grossbard is Executive Vice President and Chief Medical Officer at Rigel Pharmaceuticals (Nasdaq: RIGL). He joined Rigel as Senior Vice President of Medical Development in April 2002. Prior to joining Rigel, Dr. Grossbard was Vice President, Clinical Affairs for Avigen Inc., and he served as Senior Vice President of Development and Vice President of Medical and Regulatory Affairs at Scios, Inc. From 1982 through 1990, Dr. Grossbard held the position of Associate Director, Clinical Research, and was most recently Director, Clinical Research, at Genentech, Inc. Dr. Grossbard joined Genentech from Hoffman-LaRoche where he held various positions in clinical research. Prior to this, Dr. Grossbard held numerous academic appointments at Memorial Sloan-Kettering and Cornell University Medical Center, including Director of the adult bone marrow transplant program at Memorial Sloan-Kettering. Dr. Grossbard received his B.A. from Columbia College and his M.D. from Columbia University. In addition, he received a M.S. in Law from Yale University School of Law. He trained in Medicine at Massachusetts General Hospital and in Hematology at Columbia University and Sloan-Kettering.

About VentiRx Pharmaceuticals

VentiRx Pharmaceuticals Inc. is a biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of cancer, infectious, respiratory and autoimmune diseases. Founded in June 2006, VentiRx has assembled a team of biotechnology professionals with decades of business development and drug development experience in various therapeutic areas, with a particular expertise in innate immunity. The Company's initial focus is on developing small molecule TLR-based product candidates for oncology and allergy. VentiRx is a privately held organization headquartered in San Diego with operations in Seattle. For additional information, please visit http://www.ventirx.com.


'/>"/>
SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. West Pharmaceutical Services to Present at the 2008 UBS Global Specialty & Generic Pharmaceuticals Conference
2. Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation
3. MAP Pharmaceuticals to Present at the 2008 Citi Investment Research Global Healthcare Conference
4. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
5. Transdel Pharmaceuticals Closes $4 Million Financing
6. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Sagent Pharmaceuticals Provides US$20,000 in Aid to Earthquake-Devastated Areas in Central China
8. Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
9. Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
10. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... ... September 18, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, announces Bryan Coddington and ... Transformation in Medical Device – The Journey to FDA Compliant Field Service and ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... introduces its flexible scientist program (FSP)-- a flexible business approach similar to ... which combines SSCI’s extensive project-based analytical and solid-state chemistry services and expertise ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... its extensive experience with Health Economics and Outcomes Research (HEOR) and ‘big data’ ... testing. In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent ...
(Date:9/14/2017)... DC (PRWEB) , ... September 14, 2017 , ... AIM ... IT, Medical Tracking Systems Inc. has won the 2017 Case Study Competition for AIDC. ... technologies which provide benefits that decrease risk” and push the adoption of automated data ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):